- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00524459
Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
Phase II Study of Neoadjuvant Pegylated Liposomal Doxorubicin and Docetaxel in Locally Advanced Operable Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them before surgery may kill more tumor cells.
PURPOSE: This phase II trial is studying the side effects of giving liposomal doxorubicin together with docetaxel before surgery and to see how well it works in treating women with locally advanced breast cancer that can be removed by surgery.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
OBJECTIVES:
Primary
- To evaluate the rate of pathological complete response and clinical complete response in women with locally advanced breast cancer treated with pegylated doxorubicin hydrochloride liposome and docetaxel.
Secondary
- To assess the overall clinical local regional response in patients treated with this preoperative chemotherapy regimen.
- To evaluate the number of patients who would have required a mastectomy upfront but who underwent breast conservation therapy instead after neoadjuvant chemotherapy.
- To assess the safety, particularly with regard to neutropenia and cardiac toxicity, of pegylated doxorubicin hydrochloride liposome and docetaxel.
OUTLINE: This is a multicenter study.
Patients receive pegylated doxorubicin hydrochloride liposome IV over 90 minutes and docetaxel IV over 90 minutes on day 1. Patients receive pegylated filgrastim subcutaneously on days 2 or 3 post-chemotherapy in courses 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Within 8 weeks after completion of chemotherapy, patients undergo a lumpectomy or mastectomy to remove the tumor. Some patients may receive additional therapy after surgery, including hormonal therapy, chemotherapy, or radiotherapy.
After completion of study therapy, patients are followed periodically for up to 5 years.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
New York
-
Buffalo, New York, Estados Unidos, 14263-0001
- Roswell Park Cancer Institute
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed breast cancer using core biopsies
- Locally advanced disease
- Resectable disease
- Fine needle aspiration cytology allowed and must demonstrate invasive adenocarcinoma
- No more than 8 weeks since initial cytologic or histologic diagnosis of breast cancer
Tumor must meet the following criteria:
- Palpable on clinical examination and confined to either the breast or to the breast and ipsilateral axilla
- Measured clinically as greater than 2 cm in size (T2)
Patients with skeletal pain are eligible if bone scan and/or roentgenological examination fail to disclose metastatic disease
- Suspicious findings must be confirmed as benign by x-ray, MRI scan, or biopsy
- Hormonal status not specified
PATIENT CHARACTERISTICS:
Inclusion criteria:
- Female
- Menopausal status not specified
- ECOG performance status 0-2
- Life expectancy ≥ 10 years
- Platelet count ≥ 100,000/mm³
- ANC ≥ 1,500/mm³
- Hemoglobin ≥ 9.0 g/dL
- Bilirubin normal
- AST or ALT normal
- Alkaline phosphatase normal
- Serum creatinine normal
- Negative pregnancy test
- Fertile patients must use effective contraception (e.g., abstinence, intrauterine device, barrier device with spermicide, or surgical sterilization) during and for 3 months after completion of study therapy
- Normal cardiac function by LVEF or MUGA scan
Patients with prior non-breast malignancies are eligible if they have been disease-free for ≥ 10 years
The following are allowed even if diagnosed within the past 10 years:
- Squamous or basal cell carcinoma of the skin that has been effectively treated
- Carcinoma in situ of the cervix that has been treated by operation only
- Lobular carcinoma in situ of the ipsilateral or contralateral breast treated by segmental resection only
Exclusion criteria:
- Pregnant or lactating women
- Male patients
- Hyperbilirubinemia
Female patients with 1 or more of the following conditions:
Ulceration, erythema, infiltration of the skin (complete fixation), or peau d'orange (edema) of any magnitude
- Tethering or dimpling of the skin or nipple inversion should not be interpreted as skin infiltration
- Ipsilateral lymph nodes that are clinically fixed to one another or to other structures (N2 disease)
- Bilateral malignancy or a mass in the opposite breast suspicious for malignancy, unless there is biopsy proof that the mass is not malignant
- Suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or infraclavicular nodes, unless there is biopsy evidence that these are not involved with the tumor
- Nonmalignant systemic disease (e.g., cardiovascular, renal, or hepatic) that would preclude study therapy
Active cardiac disease that would preclude the use of doxorubicin hydrochloride, including any of the following:
- Documented myocardial infarction
- Angina pectoris that requires the use of antianginal medication
- History of documented New York Heart Association class II-IV heart failure
- Valvular disease with documented cardiac function compromise
Poorly controlled hypertension (i.e., diastolic BP > 100 mm Hg)
- Patients with well-controlled hypertension and on medication are eligible for study
- Psychiatric or addictive disorders that would preclude obtaining informed consent
PRIOR CONCURRENT THERAPY:
Inclusion criteria:
- Concurrent noncancer therapies allowed if used for conditions other than breast cancer
- Adjuvant therapy after surgery allowed
Exclusion criteria:
- Prior radiotherapy, chemotherapy, immunotherapy, and/or hormonal therapy for breast cancer
- Prior anthracycline therapy for any condition
- Concurrent hormonal therapy including tamoxifen, aromatase inhibitors, or raloxifene
- Concurrent sex hormonal therapy including birth-control pills or ovarian hormonal replacement therapy
- Concurrent other cancer therapy
- Concurrent herbal or alternative therapies for breast cancer
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Pathological Complete Response
Periodo de tiempo: Mammogram done pre-treatment and after four and six cycles of study chemotherapy treatment.
|
Mammogram done pre-treatment and after four and six cycles of study chemotherapy treatment.
|
Clinical Complete Response
Periodo de tiempo: Surgery done after completion of six cycles of study chemotherapy treatment.
|
Surgery done after completion of six cycles of study chemotherapy treatment.
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Overall Clinical Local Regional Response
Periodo de tiempo: Mammogram done pre-treatment and after four and six cycles of study chemotherapy treatment.
|
Mammogram done pre-treatment and after four and six cycles of study chemotherapy treatment.
|
Number of Women Who Would Have Required a Mastectomy Upfront But Who Underwent Breast Conservation Therapy Instead After Neoadjuvant Chemotherapy
Periodo de tiempo: Baseline (pre-treatment) surgical assessment, and post-chemotherapy surgical outcome.
|
Baseline (pre-treatment) surgical assessment, and post-chemotherapy surgical outcome.
|
Safety, in Terms of Neutropenia and Cardiac Toxicity
Periodo de tiempo: Every cycle during study treatment and 8 weeks post-treatment.
|
Every cycle during study treatment and 8 weeks post-treatment.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Tracey O'Connor, MD, Roswell Park Cancer Institute
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades de la piel
- Neoplasias
- Neoplasias por sitio
- Enfermedades de los senos
- Neoplasias de mama
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Agentes antineoplásicos
- Moduladores de tubulina
- Agentes antimitóticos
- Moduladores de mitosis
- Inhibidores de la topoisomerasa II
- Inhibidores de la topoisomerasa
- Antibióticos, Antineoplásicos
- Docetaxel
- Doxorrubicina
- Doxorrubicina liposomal
Otros números de identificación del estudio
- I 75506
- RPCI-I-75506
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de mama
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University y otros colaboradoresTerminadoLa guía de aplicación clínica de Conebeam Breast CTPorcelana
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
Ensayos clínicos sobre docetaxel
-
Nereus Pharmaceuticals, Inc.TerminadoCáncerEstados Unidos, Australia, India, Chile, Brasil, Argentina
-
Optimal Health ResearchTerminadoCáncer de mama | Cáncer de pulmón | Cancer de prostataEstados Unidos
-
Tianjin Medical University Cancer Institute and...Reclutamiento
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Pulmonary Hospital, Shanghai, ChinaTerminadoCáncer de pulmón de células no pequeñas (CPCNP)Porcelana
-
National Cancer Center, KoreaSeoul National University Bundang Hospital; Gachon University Gil Medical Center y otros colaboradoresDesconocidoCáncer gástricoCorea, república de
-
Zhuhai Beihai Biotech Co., LtdTerminadoTumores Sólidos | Bioequivalencia | DocetaxelIndia
-
Arog Pharmaceuticals, Inc.RetiradoCarcinoma de pulmón de células no pequeñas
-
SanofiTerminadoNeoplasias PulmonaresFrancia, Países Bajos, España, Pavo, Bélgica, Finlandia, Italia, Reino Unido
-
SanofiTerminadoNeoplasias de Cabeza y CuelloFrancia
-
Fudan UniversityAún no reclutandoCáncer de pulmón de células no pequeñas avanzado